8329 — Shenzhen Neptunus Interlong Bio-technique Share News
0.000.00%
- HK$152.70m
- HK$81.58m
- CNY972.01m
China's Neptunus Interlong H1 revenue falls
Brief: Shenzhen Neptunus Interlong Bio-Technique Expects Net Profit Attributable To Owners Of RMB 7 Million For 2026 Interim Period
Brief: Shenzhen Neptunus Interlong Bio-Technique Posts FY Loss & Total Comprehensive Expenses Attributable RMB40.7 Million
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees FY Net Loss Attributable Of RMB40 Million
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees Decrease In Profit Attributable For Year
Brief: Shenzhen Neptunus Interlong Bio-Technique Expects 80%-120% Decrease In Profit Attributable For Year
Brief: Shenzhen Neptunus Interlong Bio-Technique Says Neptunus Group Has Terminated Agreements Relating To Share Transfer With Textile Group
Brief: Shenzhen Neptunus Interlong Bio-Technique Says Textile Group To Buy Shares Of Neptunus Bio-Engineering
Brief: Shenzhen Neptunus Interlong Bio-Technique Sees Decrease Of More Than 50% In Profit Attributable For Year
Brief: Shenzhen Neptunus Interlong Bio-Technique Says Zhang Xiao Guang Appointed As Executive Director
Brief: Shenzhen Neptunus Interlong Bio-Technique Proposes Zhang Feng Be Re-Elected As Exec Director
Brief: Shenzhen Neptunus Interlong Bio-Technique Records Qtrly Profit Attributable RMB15.5 Mln
Brief: Shenzhen Neptunus Interlong Bio-Technique Says Unit Entered Distribution Agreement
Brief: Shenzhen Neptunus Interlong Bio-Technique Posts FY Profit RMB36 Mln
Brief: Shenzhen Neptunus Interlong Bio-Technique Says Co Unable To Publish Audited Annual Results For FY2021 On Or Before 31 March
Brief: Shenzhen Neptunus Interlong Bio-Technique's Unit Served With Notice
Brief: Shenzhen Neptunus Interlong Bio-Technique Says Bought 51% Stake In Beijing Zhongxin Pharma
Brief: Shenzhen Neptunus Interlong Bio-Technique Says Zhou Hang Resigned As Executive Director
Brief: Shenzhen Neptunus Interlong Bio-Technique Announces Passing Of Consistency Evaluation For Norfloxacin Capsules